Gyre Therapeutics, Inc.
- Open
- 6.58
- Day high
- 6.59
- Day low
- 6.45
- Prev close
- 6.59
- Volume
- 41K
- Mkt cap
- $604M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 6.0
- P/S
- 5.2
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$876K over the last 3 months (0 open-market buys, 16 sales)
- 🏛Institutions accumulating (13F)
Gyre Therapeutics, Inc. (GYRE) is a Healthcare company listed on NASDAQ. The stock is down 12% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 16 sales (SEC Form 4).
Gyre Therapeutics, Inc. (GYRE) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
GYRE earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $-0.06 | $-0.05 | +16.7% | $23M | -28.8% |
| Mar 12, 2026 | $0.06 | $0.04 | -29.4% | $37M | +5.0% |
| Nov 7, 2025 | $0.05 | $0.06 | +20.0% | $31M | -15.8% |
| May 9, 2025 | $0.03 | $0.03 | +0.0% | $22M | -23.1% |
| Mar 17, 2025 | $0.04 | $0.01 | -75.0% | $28M | +18.6% |
| Nov 13, 2024 | — | $0.02 | — | $25M | — |
| May 9, 2024 | — | $0.04 | — | $27M | — |
| Oct 26, 2023 | $-0.75 | $-1.05 | -40.0% | $31M | — |
| Aug 14, 2023 | $-0.07 | $-0.07 | +0.0% | $26M | — |
| May 15, 2023 | $-1.05 | $0.14 | +113.5% | $24M | — |
| Nov 14, 2022 | $-1.50 | $-0.05 | +96.4% | $29M | — |
| Aug 15, 2022 | $-3.67 | $0.08 | +102.1% | $23M | — |
GYRE insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 30, 2026 | Nussbaum Rodney Ldirector | Grant | 40,000 | $5.95 |
| Jun 30, 2026 | Carmichael Gordondirector | Grant | 40,000 | $5.95 |
| Jun 30, 2026 | Epstein David M.director | Grant | 40,000 | $5.95 |
| Jun 30, 2026 | Weng Dandirector | Grant | 40,000 | $5.95 |
| Jun 30, 2026 | Parry Renatedirector | Grant | 40,000 | $5.95 |
| Jun 30, 2026 | Zhang Pingdirector | Grant | 40,000 | $5.95 |
| Jun 22, 2026 | Ye Weiguoofficer: Chief Operating Officer | Sell | 5,000 | $6.24 |
| Jun 22, 2026 | Ye Weiguoofficer: Chief Operating Officer | Option | 3,000 | $0.75 |
| Jun 22, 2026 | Ye Weiguoofficer: Chief Operating Officer | Sell | 3,000 | $6.15 |
| Jun 22, 2026 | Ye Weiguoofficer: Chief Operating Officer | Option | 5,000 | $0.75 |
| Jun 15, 2026 | Ye Weiguoofficer: Chief Operating Officer | Option | 2,800 | $0.75 |
| Jun 15, 2026 | Ye Weiguoofficer: Chief Operating Officer | Sell | 2,800 | $6.17 |
| Jun 11, 2026 | Ye Weiguoofficer: Chief Operating Officer | Option | 6,418 | $0.75 |
| Jun 11, 2026 | Ye Weiguoofficer: Chief Operating Officer | Option | 14,500 | $0.75 |
| Jun 11, 2026 | Ye Weiguoofficer: Chief Operating Officer | Sell | 14,500 | $6.14 |
Source: GYRE SEC Form 4 filings, latest Jun 30, 2026. For informational purposes only — not investment advice.
See the full GYRE insider & 13F page →Gyre Therapeutics, Inc. company profile
Overview
Gyre Therapeutics, Inc. (NASDAQ:GYRE) is a pharmaceutical company founded in 2002 and headquartered in San Diego, California. The company went public in 2006 and operates as a subsidiary of GNI USA, Inc. Gyre specializes in developing and commercializing small-molecule drugs that target organ fibrosis, a medical condition where healthy tissue is replaced by scar tissue, leading to organ dysfunction. The company has successfully brought its lead drug to market and maintains an active pipeline of treatments for various fibrotic diseases affecting the lungs, liver, and other organs.
Business
Gyre Therapeutics operates in the biotechnology sector, specifically focusing on anti-inflammatory and anti-fibrotic drug development. Fibrosis is a pathological process where normal tissue is replaced by fibrous connective tissue, similar to scar formation, which can impair organ function and potentially lead to organ failure if left untreated. The company's primary commercial product is ETUARY (Pirfenidone), an anti-fibrotic medication approved for treating idiopathic pulmonary fibrosis (IPF). IPF is a progressive lung disease where lung tissue becomes scarred and thickened over time, making it increasingly difficult for patients to breathe. Pirfenidone works by reducing inflammation and slowing the formation of scar tissue in the lungs. Beyond its approved indication, ETUARY is currently undergoing Phase 3 clinical trials for several other fibrotic conditions including dermatomyositis (a muscle and skin inflammatory disease), systemic sclerosis-associated interstitial lung disease (lung scarring related to an autoimmune condition), pneumoconiosis (lung disease caused by inhaling dust particles), and diabetic kidney disease. The company's development pipeline includes F351 (Hydronidone), a structural derivative of Pirfenidone currently in Phase 3 studies for chronic hepatitis B liver fibrosis and Phase 1 studies for liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Additional pipeline candidates include F573 for acute liver failure (Phase 2), F528 for chronic obstructive pulmonary disease (preclinical), and F230 for pulmonary arterial hypertension (preclinical).
Revenue model
Gyre Therapeutics generates revenue primarily through product sales of its approved drug ETUARY (Pirfenidone). The company's customers are healthcare providers, hospitals, and patients who require treatment for idiopathic pulmonary fibrosis. Based on recent financial data, the company generated approximately $106 million in revenue for fiscal year 2024, representing a successful commercialization of its lead product. The business model relies on developing proprietary small-molecule drugs through clinical trials and obtaining regulatory approval for specific indications. Once approved, the company markets and sells these drugs to treat patients with fibrotic diseases. The company's revenue potential can expand significantly as it gains approval for additional indications of existing drugs or brings new compounds to market. Several factors influence the company's profitability margins. Positive factors include the specialized nature of fibrotic disease treatments, which often command premium pricing due to limited treatment options, and the potential for label expansion of existing drugs to new indications without proportional increases in development costs. The company's strong intellectual property position around its drug compounds also supports pricing power. Negative margin pressures include the high costs associated with conducting Phase 3 clinical trials across multiple indications, regulatory compliance expenses, and potential competition from other pharmaceutical companies developing similar anti-fibrotic treatments. Additionally, healthcare reimbursement policies and pricing pressure from payers can impact profitability. The company's cash flow from operations has been negative in recent quarters, indicating ongoing investment in research and development activities.
Competitive moat
Gyre Therapeutics possesses a moderate competitive moat built primarily around its specialized expertise in anti-fibrotic drug development and its established commercial presence in treating idiopathic pulmonary fibrosis. The company's deep understanding of fibrosis mechanisms and its proven ability to successfully develop and commercialize Pirfenidone provides valuable know-how that competitors would need years to replicate. The company's intellectual property portfolio around its drug compounds, particularly the structural derivatives like Hydronidone, creates some barriers to direct competition. Additionally, the regulatory approval process for new drugs creates natural barriers, as competitors would need to conduct their own extensive clinical trials to bring alternative treatments to market. However, the moat is not exceptionally strong. The biotechnology industry is highly competitive, with large pharmaceutical companies possessing significantly greater resources for drug development and commercialization. Major players like Roche, which markets a competing anti-fibrotic drug called Ofev (nintedanib) for similar indications, represent substantial competitive threats. The relatively small size of Gyre compared to pharmaceutical giants limits its ability to compete on marketing spend and global distribution. The company also faces the risk of generic competition once patent protections expire, and the potential for breakthrough therapies from other companies that could offer superior efficacy or safety profiles. The specialized nature of fibrotic diseases, while providing some protection, also limits the total addressable market size compared to more common therapeutic areas.
Risks & safety
Gyre Therapeutics presents a moderate margin of safety profile with several positive financial indicators but some areas of concern. • Liquidity and Solvency: The company maintains a strong current ratio of 3.36 and quick ratio of 3.19, indicating solid short-term liquidity. Cash and short-term investments of $15 million provide operational runway, though this is relatively modest for a biotech company. • Debt Position: Very low debt-to-equity ratio of 0.023 indicates minimal financial leverage and reduced solvency risk. • Cash Flow Concerns: Negative operating cash flow of -$3.6 million for fiscal 2024 and negative free cash flow of -$6.0 million indicate ongoing cash burn, though the company remains profitable on a net income basis. • Valuation Metrics: Trading at a P/E ratio of 85.2x and EV/EBITDA of 57.2x, suggesting the stock is priced for significant growth expectations. Price-to-book ratio of 16.3x indicates substantial premium to book value. • Profitability: Positive net income of $17.9 million for fiscal 2024 and return on equity of 19.1% demonstrate current profitability, though this represents a significant improvement from the -$85.5 million loss in 2023. • Other Considerations: Revenue growth trajectory and pipeline progression will be critical for justifying current valuation levels.
Recent development
Based on the financial progression over recent years, Gyre Therapeutics has undergone a significant transformation from a development-stage company to a profitable commercial entity. The most notable development was the successful commercialization of ETUARY (Pirfenidone), which drove revenue from less than $1 million in 2022 to over $105 million in 2024. The company has strategically expanded its clinical development program, advancing multiple Phase 3 studies for ETUARY in new indications including dermatomyositis, systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. This label expansion strategy represents a cost-effective approach to growth, leveraging the existing safety and efficacy profile of Pirfenidone in new therapeutic areas. Simultaneously, the company has advanced its next-generation compound F351 (Hydronidone) through clinical development, with Phase 3 studies for chronic hepatitis B liver fibrosis and Phase 1 studies for NASH-related liver fibrosis. This represents an important pipeline diversification beyond pulmonary applications into liver diseases. The financial turnaround from significant losses in 2023 to consistent profitability in 2024 demonstrates the company's successful transition to commercial operations. However, the negative operating cash flow indicates continued substantial investment in research and development activities to support the expanded clinical program across multiple indications and compounds.
GYRE company profile · for informational purposes only — not investment advice.
Track GYRE with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free